BiotechTube

ISV-303

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ocular Inflammation

Conditions

Ocular Inflammation

Trial Timeline

May 1, 2013 → Nov 1, 2013

NCT ID
NCT01808547

About ISV-303

ISV-303 is a phase 3 stage product being developed by Sun Pharmaceutical for Ocular Inflammation. The current trial status is completed. This product is registered under clinical trial identifier NCT01808547. Target conditions include Ocular Inflammation.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT01808547Phase 3Completed
NCT01576952Phase 3Completed

Competing Products

20 competing products in Ocular Inflammation

See all competitors
ProductCompanyStageHype Score
lotilaner + VehicleTarsus PharmaceuticalsPhase 2
47
Mirabegron + PlaceboAstellas PharmaPhase 1
33
ISV-303 + ISV-303 + DuraSite Vehicle + Xibrom™Sun PharmaceuticalPhase 1/2
41
ISV-303Sun PharmaceuticalPhase 3
77
ONO-9054 + LatanoprostOno PharmaceuticalPhase 2
52
ONO-9054 + PlaceboOno PharmaceuticalPhase 1
33
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Santen PharmaceuticalPhase 3
77
Tafluprost, timolol maleateSanten PharmaceuticalPre-clinical
23
DE-111 ophthalmic solutionSanten PharmaceuticalPhase 3
77
DE-117 ophthalmic solution + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
77
STN1012600 ophthalmic solution 0.002% + Latanoprost ophthalmic solution 0.005%Santen PharmaceuticalPhase 3
77
DE-117 + Latanoprost ophthalmic solutionSanten PharmaceuticalPhase 3
77
DE-117 ophthalmic solution + Timolol ophthalmic solutionSanten PharmaceuticalPhase 3
77
A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL + A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mLSanten PharmaceuticalPhase 3
77
Omaveloxolone Ophthalmic Suspension 1.0% + Omaveloxolone Opthalmic Suspension 0.5% + PlaceboAbbViePhase 2
52
AZD4017 + Placebo + AZD4017 + PlaceboAstraZenecaPhase 2
52
dorzolamide hydrochloride (+) timolol maleateMerckApproved
85
INS115644 Ophthalmic Solution + Placebo + INS115644 Ophthalmic Solution + INS115644 Ophthalmic Solution + INS115644 Ophthalmic SolutionMerckPhase 1
33
SAD448NovartisPhase 1
33
MGV354 ophthalmic suspension + MGV354 placeboNovartisPhase 1/2
41

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85